Articles
Summary of Findings From the Pivotal Phase 2 Study of Single-Agent Carfilzomib (PX-171-003-A1) in Patients With Relapsed and Refractory Multiple Myeloma
Multiple Myeloma: Nursing Considerations of Treatment With Carfilzomib
Carfilzomib for Relapsed and Refractory Multiple Myeloma: The Pharmacist’s Perspective
Carfilzomib: A Payer’s Perspective
To sign up for our newsletter or print publications, please enter your contact information below and click "Subscribe".
